Abstract:Importance: The American Joint Committee on Cancer (AJCC) eighth edition staging manual introduced a new prognostic stage for breast cancer incorporating biologic factors in addition to traditional anatomic factors. Objective: To perform a validation study of the AJCC eighth edition prognostic stage in a single-institution cohort and a large population database. Design, setting, and participants: Patients with breast cancer treated with surgery as an initial intervention were identified in a prospective institutional database from The University of Texas MD Anderson Cancer Center and the California Cancer Registry. Vital status data were complete through December 31, 2016, in The University of Texas MD Anderson cohort and through December 31, 2014, in the California Cancer Registry cohort. Patients receiving neoadjuvant systemic therapy, those with inflammatory or rare breast cancers, and those with unknown clinicopathologic factors were excluded. Factors evaluated included T, N, and M categories and tumor grade, as well as estrogen receptor, progesterone receptor, and HER2 status. Main outcomes and measures: Disease-specific survival was calculated by the Kaplan-Meier method. The Harrell concordance index (C index) was used to quantify models' predictive performance, and the Akaike information criterion (AIC) was used to compare model fits. Results: A total of 3327 patients with stage I to IIIC breast cancer treated between 2007 and 2013 at The University of Texas MD Anderson Cancer Center (median follow-up of 5 years) with complete clinicopathologic data were identified. Compared with the AJCC anatomic stage, the prognostic stage upstaged 29.5% of patients and downstaged 28.1%. The prognostic stage (C index, 0.8357 and AIC, 816.8) provided more accurate stratification with respect to disease-specific survival than the anatomic stage (C index, 0.737 and AIC, 1039.8) (P < .001 for the C index). A total of 54 727 patients with stage I to IV breast cancer treated between 2005 and 2009 were identified in the California Cancer Registry (median follow-up of 7 years). The prognostic stage upstaged 31.0% of patients and downstaged 20.6%. The prognostic stage (C index, 0.8426 and AIC, 80 661.68) performed better than the anatomic stage (C index, 0.8097 and AIC, 81 577.89) (P < .001 for the C index). Conclusions and relevance: The prognostic stage provided more accurate prognostic information than the anatomic stage alone in both a single-institution cohort and a large population database, thereby supporting its use in breast cancer staging.

Impact of Tumor Grade on Prognosis in Pancreatic Cancer: Should We Include Grade in AJCC Staging?

Impact of Tumor Grade on Pancreatic Cancer Prognosis: Validation of a Novel TNMG Staging System

Equipping the American Joint Committee on Cancer Staging for Resectable Pancreatic Ductal Adenocarcinoma with Tumor Grade: A Novel Staging System

Refined prognostic staging for resected pancreatic cancer by modified stage grouping and addition of tumour grade

A Real-Life Treatment Cohort of Pancreatic Neuroendocrine Tumors: High-grade Increase in Metastases Confers Poor Survival

New staging classification for pancreatic neuroendocrine neoplasms combining TNM stage and WHO grade classification [ ]

Incorporating Tumor Characteristics to the American Joint Committee on Cancer Breast Cancer Staging System

The effect of the American Joint Committee on Cancer eighth edition on breast cancer staging and prognostication

Distinct Survival Outcomes in Subgroups of Stage III Pancreatic Cancer Patients: Taiwan Cancer Registry and Surveillance, Epidemiology and End Results registry

Prognostic significance of grade of malignancy based on histopathological differentiation and Ki-67 in pancreatic ductal adenocarcinoma

Validation Study of the American Joint Committee on Cancer Eighth Edition Prognostic Stage Compared With the Anatomic Stage in Breast Cancer

A Novel Scoring System Predicts Postsurgical Survival and Adjuvant Chemotherapeutic Benefits in Patients with Pancreatic Adenocarcinoma: Implications for AJCC-TNM Staging

Influence of tumour grade on disease survival in male breast cancer patients: a systematic review

Updates on Grading and Staging of Prostate Cancer

Tumor Size and Perineural Invasion Predict Outcome of Gastric High-Grade Neuroendocrine Neoplasms

Preoperative Prognostic Prediction for Stage I Lung Adenocarcinomas: Impact of the Computed Tomography Features Associated with the New Histological Grading System

The Eighth Edition of the American Joint Committee on Cancer Distant Metastases Stage Classification for Metastatic Pancreatic Neuroendocrine Tumors Might Be Feasible for Metastatic Pancreatic Ductal Adenocarcinomas

Prognostic validity of the American joint committee on cancer eighth edition staging system for well-differentiated pancreatic neuroendocrine tumors

Application of the Eighth Edition of the American Joint Committee on Cancer Staging for Pancreatic Adenocarcinoma.

Grading Solid Pseudopapillary Tumors of the Pancreas: the Fudan Prognostic Index